Shattuck Labs(US:STTK) Globenewswire·2026-03-05 11:15Core Viewpoint - Shattuck Labs, Inc. is advancing its lead product candidate, SL-325, a first-in-class DR3 blocking antibody, with ongoing clinical trials and promising financial results, indicating a strong potential for growth in the biotechnology sector focused on inflammatory and immune-mediated diseases [1][2][3]. Financial Results - As of December 31, 2025, Shattuck reported cash and cash equivalents of approximately $78.1 million, an increase from $73.0 million in 2024 [10]. - Research and Development (R&D) expenses for Q4 2025 were $9.1 million, down from $15.4 million in Q4 2024, and total R&D expenses for the year were $35.3 million compared to $67.2 million in 2024 [10]. - General and Administrative (G&A) expenses for Q4 2025 were $4.3 million, slightly up from $4.2 million in Q4 2024, while total G&A expenses for the year decreased to $17.2 million from $19.1 million in 2024 [10]. - The net loss for Q4 2025 was $12.6 million, or $0.12 per share, compared to a net loss of $18.7 million, or $0.37 per share, in Q4 2024 [10]. Clinical Development - SL-325 is currently in a Phase 1 clinical trial, with data expected to be released in Q2 2026, and a Phase 2 trial in Crohn's disease anticipated to start in Q3 2026 [5][6]. - The Phase 1 trial aims to evaluate safety, tolerability, immunogenicity, and pharmacokinetics, with full enrollment expected to be completed in Q2 2026 [6]. - Shattuck is also developing multiple DR3-based bispecific antibodies, with the lead bispecific antibody entering IND-enabling activities [6]. Management Updates - Michael Choi, M.D., was appointed as Vice President of Clinical Development in November 2025, bringing significant experience in inflammatory bowel disease programs [3]. Upcoming Events - Shattuck plans to participate in several investor conferences, including the Leerink Global Healthcare Conference from March 8-11, 2026, where the CEO will present [11].